Form 4: C4 Therapeutics Director Glenn Dubin Acquires Shares in Lieu of Cash Compensation

Glenn Dubin, a director at C4 Therapeutics, acquired 1,358 shares of common stock in lieu of cash compensation, according to a recent SEC filing.

Summary

• Glenn Dubin, a director of C4 Therapeutics, acquired 1,358 shares of the company's common stock on April 1, 2024.
• The shares were issued as part of the company's Non-Employee Director Compensation Policy, with Dubin electing to receive shares instead of cash.
• The price per share was $8.1, based on the closing market price on April 1, 2024.
• Following the transaction, Dubin directly owns 22,075 shares.
• Dubin also has indirect ownership through DF Investment Partners LLC (770,607 shares) and G&E Dubin Family Foundation (20,000 shares).
• Dubin disclaims beneficial ownership of shares held by DF Investment Partners LLC and G&E Dubin Family Foundation except to the extent of his pecuniary interest therein.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transaction is a routine part of director compensation and doesn't necessarily indicate a significant shift in the company's outlook.

Positives

• A director's decision to take shares in lieu of cash compensation can be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Director share acquisitions are common and closely watched as they can reflect management's sentiment about the company's prospects. This transaction is a routine part of director compensation.

Comparison to Industry Standards

• Director compensation packages often include stock options or grants to align their interests with shareholders.
• The specifics of C4 Therapeutics' Non-Employee Director Compensation Policy would need to be compared to those of peer companies in the biotechnology sector to assess its competitiveness.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock-based compensation for their directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.

Key Dates